Phase II Trial of First-Line Durvalumab and Chemotherapy in Patients With Extra-Pulmonary Small Cell Carcinoma

Introduction: Prospective randomized trials are lacking in extensive-stage or metastatic extra-pulmonary small cell carcinoma (EPSCC). As a result, treatment for EPSCC is largely extrapolated from SCLC studies. Methods: This single-arm phase II trial enrolled patients with EPSCC to investigate the a...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Peey-Sei Kok, PhD, Bryan Chan, MMed (Clin Epi), Mason Aberoumand, MAppStat, Alison Zhang, PhD, Ken O’Byrne, MD, Subotheni Thavaneswaran, PhD, Frank Lin, PhD, Maya Kansara, PhD, Theresa Corpuz, BSc (Hons), Patrick Wheeler, BS, Robert John Simes, PhD, David Thomas, PhD, Chee Khoon Lee, PhD
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2026-07-01
سلاسل:	JTO Clinical and Research Reports
الموضوعات:	Small cell Durvalumab Chemo-immunotherapy Extrapulmonary small cell carcinoma EPSCC
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2666364326000652
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!